Letters to the Editor
Vol. 12 No. 1 (2020): Mediterranean Journal of Hematology and Infectious Diseases, Volume 12, 2020
Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: June 19, 2020
Accepted: July 13, 2020
Accepted: July 13, 2020
1014
Views
741
Downloads
162
HTML
Authors
Discontinuation of tyrosine kinase inhibitors (TKI) is the main goal today in the field of Philadelphia positive chronic myeloid leukemia (Ph + CML) and the criteria to attempt the interruption of therapy are well defined and rely on the possibility to regularly monitor the BCR-ABL1 transcript. Patients harboring atypical transcripts are automatically excluded from protocols due to the absence of a standardized method of quantification of their minimal residual disease (MRD). We report here the outcome of 6 patients with atypical transcripts with a long follow up whose MRD was followed in three cases with digital PCR during their treatment free remission (TFR).
Downloads
Download data is not yet available.
Citations
How to Cite
“Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts”. (2020) Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020066. doi:10.4084/mjhid.2020.066.
